Kapucuoğlu Nilgün, Bozkurt Kemal Kürşat, Başpınar Şirin, Koçer Murat, Eroğlu Hasan Erol, Akdeniz Raşit, Akçil Mehtap
Süleyman Demirel University, Faculty of Medicine, Department of Pathology, 32260 Isparta, Turkey.
Süleyman Demirel University, Faculty of Medicine, Department of Medical Oncology, 32260 Isparta, Turkey.
Pathol Res Pract. 2015 Oct;211(10):740-7. doi: 10.1016/j.prp.2015.05.011. Epub 2015 Jun 1.
Recently, there are several studies about cancer stem cells (CSC), indicating that they are the cells that initiate the tumor, provide progression, metastasis and responsible for the aggressive tumor behavior.
The purpose of this study is to investigate the expressions of CD24, CD44, their different combinations, ALDH1 and CD133 in invasive ductal carcinoma. Their relationships with clinicopathologic parameters, such as tumor grade, lymphovascular invasion, tumor size, axillary lymph node involvement, stage, hormone receptors, HER2 expression, basal like tumors, triple negative status and prognosis were also investigated. Tissue microarray method was used to investigate ımmunohistochemical CD24, CD44, ALDH1 and CD133 expressions in 105 invasive ductal carcinoma cases.
CD133 expression was significantly associated with tumor size (p=0.023) and stage (p=0.009). CD133 expression was decreased in tumors with larger tumor size, higher stage and lymphovascular invasion. CD133 expression was positively correlated with CD44 (r=0.212, p=0.032) and CD44(+)/CD24(+) (r=0.202, p=0.040) expressions. CD44, CD24 and ALDH1 expressions showed no significant relationship and correlation with clinicopathologic features. There was a significant relationship (p=0.048) between CD44(+)/CD24(-/low) phenotype and basal like tumors. EGFR expression was positively correlated with CD44(+)/CD24(-/low) phenotype (r=0.211, p=0.036).
Basal like tumors are enriched for CSCs with CD44(+)/CD24(-/low) phenotype. CD133 can detect a different population of CSC in breast carcinoma.
最近，有几项关于癌症干细胞（CSC）的研究，表明它们是启动肿瘤、促进肿瘤进展、转移并导致肿瘤侵袭性行为的细胞。
本研究的目的是调查浸润性导管癌中CD24、CD44、它们的不同组合、醛脱氢酶1（ALDH1）和CD133的表达情况。还研究了它们与临床病理参数的关系，如肿瘤分级、淋巴管浸润、肿瘤大小、腋窝淋巴结受累情况、分期、激素受体、人表皮生长因子受体2（HER2）表达、基底样肿瘤、三阴性状态及预后。采用组织芯片法检测105例浸润性导管癌病例中免疫组化CD24、CD44、ALDH1和CD133的表达。
CD133表达与肿瘤大小（p = 0.023）和分期（p = 0.009）显著相关。在肿瘤体积较大、分期较高和有淋巴管浸润的肿瘤中，CD133表达降低。CD133表达与CD44（r = 0.212，p = 0.032）和CD44(+)/CD24(+)（r = 0.202，p = 0.040）表达呈正相关。CD44、CD24和ALDH1表达与临床病理特征无显著关系和相关性。CD44(+)/CD24(-/低)表型与基底样肿瘤之间存在显著关系（p = 0.048）。表皮生长因子受体（EGFR）表达与CD44(+)/CD24(-/低)表型呈正相关（r = 0.211，p = 0.036）。
基底样肿瘤富含具有CD44(+)/CD24(-/低)表型的癌症干细胞。CD133可检测乳腺癌中不同群体的癌症干细胞。
